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An economic analysis of the National Cancer Institute of Canada 
Clinical Trials Group (NCIC CTG) BR.21, a randomized trial 
of erlotinib versus best supportive care after cisplatin based 
chemotherapy in advanced non-small-cell lung cancer (NSCLC)
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Background: NCIC CTG BR.21 is a landmark trial, establishing the 
epidermal growth factor receptor inhibitor erlotinib, as a second or 
third line treatment option for advanced NSCLC after failure of cispla-
tin based chemotherapy. Overall survival and quality of life outcomes 
were superior in the erlotinib arm compared to best supportive care, 
with an overall survival of 6.7 vs. 4.7 months (p<0.001). In view of this 
clinical beneﬁt, the cost effectiveness of erlotinib was investigated. 
Methods: Direct medical resource utilization data were collected 
from the BR.21 trial database. The analysis was performed based on 
Canadian Public Healthcare System perspective, using costs (CAD$ 
2006) from provincial sources. Direct medical costs include: drug, hos-
pitalizations; toxicity, procedures, transfusions and radiation therapy. 
Non-medical and indirect costs were not included. Average costs per 
treatment arm are calculated. 
Results: Utilization data were collected on 731 patients (100%), of 
which 488 patients were assigned to the erlotinib arm. Preliminary 
results show, an overall mean cost of erlotinib alone, per patient, is 
$10,584 and $11,642 with additional mark up fees. 
Conclusion: The predominant cost in the erlotinib arm is related to 
drug cost, but this may be within an acceptable level of health care 
expenditure. Cost effectiveness and costing in patient subgroups will be 
presented. 
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IFCT0401 trial: Phase II study of gefitinib administered as 
first-line treatment in non-resectable adenocarcinoma with 
bronchioloalveolar carcinoma features (ADC-BAC) - Does disease 
control on gefitinib affect progression free survival and overall 
survival in ADC-BAC? 
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Background: ADC-BACs are distinguished from other ADCs by 
epidemiological, clinical and CT scan presentations as well as mo-
lecular biology, leading to some responses to EGF-TKI. We therefore 
conducted a prospective, multicentric, phase II trial to evaluate geﬁtinib 
(250 mg/d) as ﬁrst-line treatment in non-resectable ADC-BAC. 
Methods: Inclusion criteria were previously untreated, non-resectable 
cyto/pathologically proven ADC-BAC. Primary objective was disease 
control rate (DCR) at 3 months. Secondary exploratory objectives were 
progression free survival (PFS), overall survival (OS), and identiﬁca-
tion of factors associated with PFS and OS using multivariate cox 
model analyses. 
Results: From 04/04 to 06/05, 88/90 enrolled patients were eligible. All 
were caucasians with stage IV disease, PS <2 in 81.8%, age >70 yrs in 
36.4%, females in 54.4% and non-smokers in 43.2%. DC was achieved 
in 25/85 evaluable patients (DCR=29.3%, CI=[20-39]). Median PFS 
was 2.9 months (CI=[2.4-3.2]) and median survival 13.3 months 
(CI=[10.1-21.8]), with a 1-year survival of 55.7% (CI=[44.4-65.5]). DC 
was independently associated with age >70 yrs (OR=4.9, p=.047); nev-
er-smoking (OR=8.1, p=.015); Respiratory Symptoms Scale (RSS) <9 
(OR=18.7, p=.002); non-mucinous BAC (OR=15.1, p=.006) and rash 
(OR=2.1, p=.02). When DC at 3 months was not included as factor in 
the cox model, reduced risk of progression was independently associ-
ated with RSS <9 (HR=0.512, p=.03); non-mucinous BAC (HR=0.316, 
p=.01) and presence of rash (HR=0.440, p=.004). However, when DC 
was included in the model, reduced risk of progression was strongly 
associated with DCR (HR=0.025, p<.0001) with independent effect 
of non-mucinous BAC histology (HR=0.380, p=.04). When DC was 
not included as factor in the cox model, decreased risk for death was 
independently associated with initial stage I-IIIa (HR=0.213, p=.01); 
absence of bronchorrhea and oxygen support (HR=0.056, p=.01 and 
HR=0.349, p=.007); RSS <9 (HR=0.363, p=.003); and presence of rash 
(HR=0.338, p=.0007). However, DC at 3 months did not affect the risk 
for OS when included in the Cox model. 
Conclusions: Geﬁtinib seems active as ﬁrst-line treatment of non-
resectable ADC-BAC especially, in older patients, never-smokers, 
patients with fewer pulmonary symptoms and with non-mucinous BAC 
subtype. While DC by geﬁtinib at 3 months strongly predicted PFS, 
it did not independently inﬂuenced survival in the IFCT0401 popula-
tion. This suggested that ADC-BAC has been controlled by second-line 
chemotherapy given after progression under geﬁtinib in some patients 
of the IFCT0401 cohort. 
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Concordance of the determination of EGFR and K-ras mutations 
in a tumor bank obtained by 15 centers in france: a pilot study of 
the ERMETIC project.
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Background: Epidermal Growth Factor - Tyrosine Kinase Inhibitors 
(EGFR-TKIs) and especially erlotinib, are authorized in Europe for 
the treatment of metastatic non-small cell lung cancer (NSCLC) after 
failure of, at least one, prior chemotherapy. Although, it has been sug-
gested that biological markers (EGFR over-expression, EGFR gene 
polysomy/ampliﬁcation and EGFR and K-ras mutations) are predictive 
of efﬁcacy of EGFR-TKIs, they are not used in clinical practice. In 
order to help implementation of these biomarkers in France, the French 
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National Cancer Institute has granted a 2-year multicentric prospective 
project entitled: Evaluation of the EGFR Mutation status for the admin-
istration of EGFR-TKIs in non small cell lung Carcinoma (ERMETIC). 
ERMETIC was constituted by 15 regional centers in France, among 
which an expert pathologists panel was formed, and an external refer-
ence molecular laboratory. ERMETIC has several consecutive objec-
tives, but the ﬁrst was to evaluate the ability of each center to perform 
biomarker assays in parafﬁn embedded tissues and the concordance of 
their results between centers, with the expert pathologists panel and an 
external molecular reference laboratory.
Methods: A tumor bank was composed by centrally collected speci-
mens from non-previously treated patients that underwent surgery. It 
was enriched by specimens harboring EGFR-mutation or obtained from 
non-smokers (NS) and females (F) with adenocarcinoma (ADC). The 
bank consisted of snap frozen and parafﬁn embedded tissues, as well as 
DNA extracts. All specimens were send blinded to the different centers 
for molecular analysis. EGFR IHC and FISH were performed by the 
3 panel pathologists on the entire tumor bank. EGFR and K-ras genes 
were sequenced by centers on their own specimens as well as on the 
DNA extracts of the entire bank, and by the molecular reference labora-
tory on all the DNA samples but also on the snap frozen specimens. 
Concordance results are presented by the percentage of discordant 
results, and by kappa coefﬁcients for observer agreement, together with 
95% conﬁdence intervals. 
Results: The tumor bank contained specimens from 74 surgically 
resected NSCLC of which 16% with known EGFR-mutation and 74% 
with ADC histology. 76% of patients were F and 49% NS. At the time 
of the abstract submission, all EGFR IHC and FISH analyses and 
EGFR and K-ras mutation sequences have been completed. Deﬁnitive 
concordance results will be presented at the IASLC meeting. 
Conclusions: The ability to study EGFR-TKIs predictive biomarkers 
of efﬁcacy in parafﬁn embedded tumor specimens by routine labora-
tories and their capacity to give concordant results are a prerequisite 
to the implementation of these techniques in the clinical practice in 
France.
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Respiratory symptoms improvement in non-resectable 
adenocarcinoma with bronchioloalveolar carcinoma features 
(ADC-BAC) treated with gefitinib: Quality of Life analysis of the 
IFCT-0401 trial
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Background: A multicenter single-arm Phase II study evaluated the ef-
ﬁcacy, safety, and tolerability of geﬁtinib (250 mg/dy) in patients with 
non-resectable ADC-BAC. A second objective was to assess respiratory 
symptoms and quality of life (QOL) improvements and their relation-
ship to disease control (DC) and objective response (OR). 
Methods: Patients received oxygen saturation measurement (SaO2), as 
well as Respiratory Symptoms Scale (RSS) evaluation and QOL assess-
ment by Saint George’s Respiratory Questionnaire (SGRQ), at baseline, 
1 month (M1), 3 months (M3) and every 3 months until progression. 
SaO2 was determined by pulse digital oxymetry. For RSS, patients 
answered each item (cough, dyspnea, wheeze, chest tightness, sputum 
production and nocturnal awakening) on a six-point scale ranging 
from 0 (none) to 4 (constant). One missing point invalidates the whole 
questionnaire. Overall function scores (0-24) were calculated, with 
lower scores reﬂecting better function and symptom response. SGRQ is 
a standardized self-administered airways disease-speciﬁc questionnaire 
divided into 3 subscales: symptoms (8 items), activity (16 items) and 
impacts (26 items). For each subscale and for the overall questionnaire, 
scores range from 0 to 100 (maximum impairment). Results of SaO2, 
RSS and SGRQ (total score) were compared at each endpoint for the 
overall population and by response categories (p value obtaining by 
paired t-test).
Results: DC rate and OR at 3 months were 29.3% and 12.9%, re-
spectively, in the 85/88 evaluable patients. The table below shows: 
(1) compliance and results of SaO2, RSS and SGRQ at baseline; (2) 
comparisons between times of evaluation (M1 or M3) and by response 
categories. Compliance with QOL was similar for SaO2, RSS and 
SGRQ and similarly decreased with time in all response categories. At 
M0, there is no statistically signiﬁcant difference of baseline results 
between response groups and the overall population. At 1 month, SaO2, 
RSS and SGRQ signiﬁcantly improved in controlled and responding 
patients, but did not improve between M1 and M3 (M3-M1, data not 
shown). Although these parameters did not deteriorate at M1 in pro-
gressors, they signiﬁcantly deteriorated at M3. 
Conclusions: These results show that: (1) QOL improvement may 
precede objective response observed with geﬁtinib and (2) absence of 
1-month QOL improvement is associated with progression at M3 (or 
before). These suggests that QOL should be an interesting surrogate 
marker of efﬁcacy as objective response is difﬁcult to assess in ADC-
BAC. Finally, because SGRQ is time consuming for patients as well 
as for analyses and progressions are mostly within the lungs, ongoing 
IFCT trials on this tumour will preferably use SaO2 and RSS for QOL 
evaluation. 
Characteristics M0 
% Mean p value
M1-M0
MD RMD % p value
M3-M0
MD RMD % p value
All (n=85)
SaO2 95 92.69 - -0.04 -0.04 NS 0.78 1.80 NS
RSS 94 9.18 - -1.06 -11.37 0.013 -0.83 -10.58 NS
SGRQ 94 42.19 - -1.38 -3.31 NS -1.78 -5.25 NS
OR (n=11)
SaO2 91 90.00 0.22 6.32 7.02 0.037 8.68 8.80 0.035
RSS 91 8.30 0.62 -6.00 -62.34 0.012 -5.57 -54.17 0.046
SGRQ 91 43.75 0.84 -18.11 -39.08 0.025 -21.12 -45.58 0.010
DCR (n=25)
SaO2 92 92.26 0.77 3.41 3.71 0.023 4.19 4.62 0.037
RSS 96 6.92 0.07 -3.21 -42.66 0.008 -2.47 -32.41 0.038
SGRQ 96 39.45 0.62 -9.78 -25.03 0.007 -11.40 -29.17 0.004
PROG (n=60)
SaO2 93 92.84 0.88 -1.43 -1.54 0.038 -2.84 -1.08 0.039
RSS 93 10.14 0.29 -0.25 -2.56 NS 1.13 13.95 NS
SGRQ 93 43.36 0.78 1.92 4.51 NS 9.53 34.02 0.044
%: compliance of paired QOL was expressed as % of expected
MD: Mean diﬀerence; RMD %: Relative Mean diﬀerence %
